Prostatic artery embolization (PAE) is a minimally invasive treatment procedure used for the treatment of benign prostatic hyperplasia (BPH) symptoms. It involves obstructing the small arteries that supply blood to the prostate gland, leading to shrinkage of the gland and relief from BPH symptoms. The procedure provides an effective alternative to traditional treatment options like medications or surgery for patients suffering from BPH, which occurs in over 50% of men aged above 50 years. PAE helps improve urinary flow and symptoms with less pain, fewer side effects and shorter recovery time as compared to transurethral resection of the prostate (TURP). Increasing preference for minimally invasive procedures along with rising global geriatric population suffering from BPH is a key driver boosting demand for PAE.
The Global Prostatic Artery Embolization Market is estimated to be valued at US$ 270.72 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Prostatic Artery Embolization Market Demand are Ingersoll-Rand plc (Nexia), Vivint, Inc., Protection One Alarm Monitoring, Inc., The ADT Corporation, Telus Communications, Frontpoint Security Solutions, AT&T Inc., Johnson Controls, Inc., Comcast Corporation, Charter Communications (TWC), and CenturyLink, Inc.
Growing awareness about the procedure and its benefits compared to other options is creating new opportunities for players in the market. National and international medical associations are also promoting PAE as a standard treatment option which is further driving its adoption.
Key players are focusing on geographic expansion strategies to tap growth opportunities in emerging markets of Asia Pacific, Latin America, and Middle East & Africa. Players are obtaining regulatory approvals and collaborating with local clinicians to educate patients and promote PAE in new regions.
Market Drivers
- Rising incidence of BPH due to growing geriatric population globally is a major factor driving the market. According to WHO, over 50% of men aged above 60 years are affected by the condition.
- Increasing preference of patients and doctors for minimally invasive procedures over traditional surgical treatments like TURP is boosting adoption of PAE. It offers advantages like quicker recovery, lesser complications, and similar clinical outcomes.
Market Restraints
- Availability of alternative treatment options like drugs, TURP, and laser procedures could limit full adoption of PAE.
- Lack of comprehensive clinical evidence, as PAE is a newer approach compared to conventional therapies, makes it less preferred by some physicians and patients.
Segment Analysis
Prostatic Artery Embolization market is dominated by the prostate artery embolization procedure segment. This is because it is a minimally invasive treatment option for benign prostatic hyperplasia (BPH) which targets the prostate adenoma by blocking the blood flow. This procedure reduces prostate size and relives BPH symptoms without surgical risks. No other segment such as embolic agents or catheter come close to this procedure segment.
Global Analysis
North America region holds the largest share in the overall Prostatic Artery Embolization market due to growing geriatric population suffering from BPH and rising healthcare expenditure. The region is expected to continue its dominance during the forecast period owing to increasing adoption of minimally invasive treatments. Asia Pacific is projected to witness the highest growth rate during the forecast period due to growing awareness about image guided therapies and rising healthcare infrastructure in emerging economies like China and India.
Get more insights on Prostatic Artery Embolization Market
Comments
0 comment